Company Overview
Solesence, Inc. operates as a science-driven entity that develops, manufactures, and sells an integrated family of technologies within the United States, with specific engagements in engineered materials, formulation development, commercial manufacturing, and the provision of skin care formulations containing mineral-based UV protection. The company functions within the Consumer Defensive sector, specifically inside the Household & Personal Products industry, where its offerings are positioned to provide essential goods that maintain steady demand regardless of broader economic cycles. This business model supports a market capitalization of $64.07M and generates annual revenue of $62.15M across an organization employing 98 individuals. These valuation and revenue figures indicate that Solesence, Inc. is a small-cap enterprise operating with a relatively limited scale compared to large-cap peers, suggesting a niche market presence where growth is heavily dependent on the expansion of its proprietary technology portfolio rather than broad volume sales.
Financial Health
The company reported a trailing twelve-month revenue of $62.15M against a net income of $1.07M and an EBITDA of $2.07M, revealing a significant gap between top-line sales and bottom-line profit that highlights a substantial cost structure burden. This disparity is further illustrated by the operating margin of -5.3%, which indicates that operational expenses currently exceed gross profits before interest and taxes. The gross margin stands at 24.8%, showing that the company retains roughly a quarter of its sales revenue after direct production costs, while the profit margin of 1.7% reflects the net impact of all operating, interest, and tax expenses on the final earnings. Financial flexibility is currently constrained by a free cash flow of -$12,682,500, meaning the company is burning cash and relying on existing liquidity to fund operations or debt obligations. The balance sheet presents a leveraged profile with $429,000 in cash holdings offset against $25.18M in total debt, resulting in a debt-to-equity ratio of 146.19 that signals a high reliance on borrowed capital relative to shareholder equity. Short-term liquidity appears manageable given a current ratio of 1.84, which suggests the firm holds sufficient current assets to cover its short-term liabilities with more than double the necessary margin. Return on equity is reported at 6.6% and return on assets at 1.4%, metrics that reveal management is generating modest returns on the capital employed, with asset efficiency being particularly low given the high leverage on the balance sheet.
Valuation Assessment
The trailing twelve-month P/E ratio is 90.83, while the forward P/E is listed as N/A, implying that analysts have not yet established a consensus on future earnings that would justify a forward multiple, likely due to the lack of recent earnings growth. The price-to-book ratio stands at 3.72, indicating that the market values the company at a significant premium of roughly 3.7 times its net asset book value, which may reflect investor confidence in the intangible value of its technology or the potential for future profitability recovery. Alternative valuation metrics such as the price-to-sales ratio of 1.03 and the EV/EBITDA of 42.97 suggest the stock is priced in line with its sales revenue but commands a high multiple relative to its earnings before interest, taxes, depreciation, and amortization. Price volatility is evident from the 52-week trading range between a low of $0.78 and a high of $16.56, placing the current valuation context within a wide band where the stock has historically experienced extreme price fluctuations. The beta of 1.06 indicates that the stock's price volatility moves in tandem with the broader market, exhibiting slightly higher sensitivity to general market swings than the average stock.
Growth & Income
Solesence, Inc. experienced a revenue growth rate of -13.5% year-over-year, while earnings growth is listed as N/A, indicating that the decline in revenue has severely impacted profitability to the point where traditional earnings growth metrics are no longer applicable. The negative revenue growth suggests that the company is currently facing headwinds in its sales channels or market share rather than benefiting from an expansion of its customer base. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are retained within the business to fund operations, debt reduction, or potential future investments. This reinvestment strategy is necessitated by the current lack of free cash flow and negative operating margins, prioritizing survival and restructuring over income distribution. The overall growth and income profile is characterized by contraction in sales and a complete absence of dividend income, reflecting a high-risk phase where capital preservation is the primary objective rather than capital appreciation through dividends.